Early appropriate empiric therapy and antimicrobial de-escalation

Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures

Volumn , Issue , 2007, Pages 231-250

  Hollands, James M ^a   Micek, Scott T ^a   McKinnon, Peggy S ^a   Kollef, Marin H ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879548237     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (66)

1. Gaynes R, Edwards JR. National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005; 41:848-54.
2. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28:429-48.
3. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21:510-5.
4. Trouillet J-L, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-9.
5. American Thoracic Society: Guidelines for the Management of Adults with Hospitalacquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
6. Vidaur L, Sirgo G, Rodriguez AH, et al. Clinical approach to the patient with suspected ventilator-associated pneumonia. Respir Care 2005; 50:965-74.
7. Babcock HM, Zack JE, Garrison T, et al. Ventilator-associated pneumonia in a multihospital system: differences in microbiology by location. Infect Control Hosp Epidemiol 2003; 24:853-8.
8. Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites. Am J Respir Crit Care Med 1999; 160:608-13.
9. Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000; 49:638-45.
10. Crouch Brewer S, Wunderink RG, Jones CB, et al. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996; 109:1019-29.
11. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150:1545-9.
12. Combes A, Luyt CE, Fagon JY, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170:786-92.
13. Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-74.
14. Rello J, Quintana E, Ausina V, Puzo C, Net A, Prats G. Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990; 142:1320-4.
15. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine Leukocidin genes. Clin Infect Dis 2005; 40:100-7.
16. Micek ST, Dunne WM, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732-8.
17. Rello J, Ausina V, Ricart M, et al. Risk Factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med 1994; 20:193-8.
18. Conway SP, Brownlee KG, Denton M, et al. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003; 2:321-32.
19. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174:529-36.
20. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coil and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
21. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36:1006-12.
22. O’Grady NP, Barie PS, Bartlett JG, et al. Practice guidelines for evaluating new fever in critically ill adult patients. Clin Infect Dis 1998; 26:1042-59.
23. Bernard GR, Vincent J-L, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
24. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-71.
25. Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869-78.
26. Baselski VS, El-Torky M, Coalson JJ, et al. The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia. Chest 1992; 102:571S-9S.
27. Shorr AF, Sherner JH, Jackson WM, et al. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 2005; 33:46-53.
28. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 2183-90.
29. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL cultures results. Chest 2005; 128:2706-13.
30. Evans HL, Raymond DP, Pelletier SJ, et al. Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care 2001; 7:117-21.
31. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.
32. Calandra T, Cohen J. The international sepsis consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005; 33:1538-48.
33. Llewelyn M, Cohen J. Diagnosis of infection in sepsis. Int Care Med 2001; 27(Suppl): S10-32.
34. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
35. Hyle EP, Lipworth AD, Zaoutix TE, et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165:1375-80.
36. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760-6.
37. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-94.
38. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-85.
39. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-20.
40. Dupont H, Mentec H, Sollet JP, et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-62.
41. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003: 31:2742-51.
42. Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-35.
43. Micek ST, Isakow W, Shannon W, et al. Predictors of hospital mortality for patients with severe sepsis treated with drotrecogin alfa (activated). Pharmacotherapy 2005; 25:26-34.
44. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-86.
45. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
46. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-11.
47. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-23.
48. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15.
49. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactum-aminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127-33.
50. Micek ST, Ward S, Fraser VJ, et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-9.
51. Dennesen PJW, van der Ven AJ, Kessels AGH, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163:1371-5.
52. Singh N, Rogers P, Atwood CW, et al. Short course empiric antibiotic therapy for pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-11.
53. Chastre J, Wolff M, Fagon JY, et al. Comparison of 15 vs. 8 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98.
54. Himmelberg CJ, Pleasants RA, Weber DJ, et al. Use of antimicrobial drugs in adults before and after removal of a restriction policy. Am J Hosp Pharm 1991; 48:1220-7.
55. Thomas AR, Cieslak PR, Strausbaugh LJ, et al. Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment. Infect Control Hosp Epidemiol 2002; 23:683-8.
56. Erbay A, Colpan A, Bodur H, et al. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int J Antimicrob Agents 2003; 21:308-12.
57. Bassetti M, Di Biagio A, Rebesco B, et al. Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy. Int J Antimicrob Agents 2000; 16:295-9.
58. Vlahovic-Palcevski V, Morovic M, Palcevski G. Antibiotic utilization at the university hospital after introducing an antibiotic policy. Eur J Clin Pharmacol 2000; 56:97-101.
59. Shah NP, Reddy P, Paladino JA, et al. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Curr Med Res Opin 2004; 20:779-90.
60. Paladino JA. Economics of antibiotic use policies. Pharmacotherapy 2004; 12:232S-8S.
61. Papadopoulos J, Rebuck JA, Lober C, et al. The critical care pharmacist: an essential intensive care practitioner. Pharmacotherapy 2002; 22:1484-8.
62. Evans RS, Classen DC, Pestotnik SL, et al. Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994; 154:878-84.
63. Pestotnik SL, Classen DC, Evans RS, et al. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124:884-90.
64. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998; 338:232-8.
65. Leibovici L, Gitelman V, Yehezkelli Y, et al. Improving empirical antibiotic treatment: prospective, nonintervention testing of a decision support system. J Intern Med 1997; 242:395-400.
66. Yates RR. New intervention strategies for reducing antibiotic resistance. Chest 1999; 115:24S-7S.